- Nutriband Inc. (NTRB, Financial) has announced a 25% preferred stock dividend for shareholders.
- The record date for eligibility is set for July 25, 2025, with distribution scheduled for August 5, 2025.
- Preferred shares offer conversion to common stock upon FDA approval of AVERSA Fentanyl.
Nutriband Inc. (NTRB) is set to issue a 25% preferred stock dividend, providing one preferred share for every four common shares held by shareholders. The pivotal dates for this dividend have been confirmed, with shareholders needing to be on record by July 25, 2025, to receive the dividend on August 5, 2025.
The preferred shares present a significant opportunity for holders as they are convertible into common stock. This conversion is contingent upon the U.S. Food and Drug Administration (FDA) approving the company's AVERSA Fentanyl product. Should the preferred shares not be converted, shareholders will be entitled to an annual cash dividend from company profits, as determined by the Board of Directors.
Nutriband's AVERSAâ„¢ technology, which is at the forefront of this announcement, is an abuse-deterrent transdermal technology aimed at reducing the misuse of drugs with high abuse potential, like fentanyl. This innovation is crucial for improving safety profiles while ensuring drugs remain accessible to patients in need. The company holds a robust patent portfolio for this technology across multiple regions, including the United States, Europe, and Asia.
The implementation of a preferred stock dividend aligns with Nutriband's long-term strategic goals as it gears up to file for FDA approval, paving the way for potential growth and shareholder value enhancement.
